Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: Single centre clinical experience from the compassionate use programme

Breast Cancer Research and Treatment

Volumn 106, Issue 1, 2007, Pages 105-112

  Mlineritsch, Brigitte ^a   Psenak, Oskar ^a   Mayer, Peter ^a   Moik, Martin ^a   Namberger, Konrad ^a   Hauser Kronberger, Cornelia ^a   Greil, Richard ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Advanced breast cancer; Endocrine resistance; Fulvestrant; Pretreatment regimens

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FULVESTRANT; PROGESTERONE RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER GROWTH; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DYSPNEA; FEMALE; FLUSHING; HORMONAL THERAPY; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; METASTASIS; NAUSEA; ONCOGENE NEU; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR CELL; VAGINA BLEEDING; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; EMPATHY; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM METASTASIS; PALLIATIVE CARE; PROGRAM EVALUATION; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 34848922170     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9482-7     Document Type: Article

References (23)

1. Howell A, Osborne CK, Morris C, Wakeling AE (2000) ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer 89(4):817-825
2. Nawaz Z, Stancel GM, Hyder SM (1999) The pure antiestrogen ICI 182,780 inhibits progestin-induced transcription. Cancer Res 59(2):372-376
3. Rajah TT, Pento JT (1999) Influence of antiestrogens on the invasiveness and laminin attachment of breast cancer cells. Cancer Invest 17(1):10-18
4. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A (2002) Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20(16):3386-3395
5. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C (2002) Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20(16):3396-3403
6. McGuire WL, Osborne CK, Clark GM, Knight WA III (1982) Steroid hormone receptors and carcinoma of the breast. Am J Physiol 243(2):E99-E102
7. Hauser-Kronberger C, Dandachi N (2004) Comparison of chromogenic in situ hybridization with other methodologies for status assessment in breast cancer. J Mol Histol 35(6):647-653
8. Erasmus JJ, Gladish GW, Broemeling L, Sabloff BS, Truong MT, Herbst RS, Munden RF (2003) Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 21(13):2574-2582
9. De Maio E, Gravina A, Pacilio C, Amabile G, Labonia V, Landi G, Nuzzo F, Rossi E, D'Aiuto G, Capasso I, Rinaldo M, Morrica B, Elmo M, Di Maio M, Perrone F, de Matteis A (2005) Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience. BMC Cancer 5:30
10. Kemmler G, Holzner B, Kopp M, Dunser M, Margreiter R, Greil R, Sperner-Unterweger B (1999) Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. J Clin Oncol 17(9):2932-2940
11. Mercier M, Schraub S, Bransfield DD, Fournier J (1992) Patient acceptance and differential perceptions of quality of life measures in a French oncology setting. Qual Life Res 1(1):53-61
12. Hakamies-Blomqvist L, Luoma M, Sjostrom J, Pluzanska A, Sjodin M, Mouridsen H, Ostenstad B, Mjaaland I, Ottosson-Lonn S, Bergh J, Malmstrom P, Blomqvist C (2000) Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group. Eur J Cancer 36(11):1411-1417
13. Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, Kabbaj O, Spano JP, Marsiglia H, Rouzier R, Delaloge S, Spielmann M (2004) Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 22(16):3302-3308
14. Hortobagyi GN (2003) Future directions in the endocrine therapy of breast cancer. Breast Cancer Res Treat 80(Suppl 1):S37-S39
15. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M; Arimidex Writing Committee; Investigators Committee Members (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92(9):2247-2258
16. Steger GG, Bartsch R, Wenzel C, Pluschnig U, Hussian D, Sevelda U, Locker GJ, Gnant MF, Jakesz R, Zielinski CC (2005) Fulvestrant (''Faslodex'') in pre-treated patients with advanced breast cancer: a single-centre experience. Eur J Cancer 41(17):2655-2661 (Epub 17 Oct 2005)
17. Ingle JN, Suman VJ, Rowland KM, Mirchandani D, Bernath AM, Camoriano JK, Fishkin PA, Nikcevich DA, Perez EA; North Central Cancer Treatment Group Trial N0032 (2006) Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 24(7):1052-1056
18. Nicholson RI, Gee JM, Knowlden J, McClelland R, Madden TA, Barrow D, Hutcheson I (2003) The biology of antihormone failure in breast cancer. Breast Cancer Res Treat 80(Suppl 1):S29-S34; discussion S35
19. Pietras RJ, Marquez DS, Chen HW et al (2003) Improved antitumour therapy with Herceptin and Faslodex for dual targeting of HER-2 and estrogen receptor signalling pathways in human breast cancers with overexpression of HER-2/neu gene. Breast Cancer Res Treat 82(Suppl 1):S12 (abstract 22)
20. Steger GG, Gips M, Simon SD, Lluch A, Vinholes J, Kaufman B, Wardley A, Mauriac L (2005) Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use Programme. Cancer Treat Rev 31(Suppl 2):S10-S16 (Epub 28 Sep 2005)
21. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J; ABCSG, the GABG (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366(9484):455-462
22. Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Jakesz R (2005) Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: a meta-analysis of the ARNO 95 Trial, ABCSG Trial 8 and the ITA Trial. Breast Cancer Res Treat (abstract 18)
23. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS; ATAC Trialists' Group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365(9453):60-62